Product Description
Erlotinib is a tyrosine kinase receptor inhibitor that is used in the therapy of advanced or metastatic pancreatic or non-small cell lung cancer. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation. This helps slow or stop the spread of cancer cells. Erlotinib is the first such drug to demonstrate an increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer.
